Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1985 Jun;60(3):489–495.

Depressed classical complement pathway activities in chronic lymphocytic leukaemia.

G Füst, E Czink, D Minh, Z Miszlay, L Varga, S R Hollán
PMCID: PMC1577204  PMID: 4017286

Abstract

Haemolytic activities of the classical and alternative complement pathways, and levels of C1, C4, C3, factor B and C1 inhibitor (C1-INH) were measured in 85 serum samples from 46 patients with chronic lymphocytic leukaemia (CLL). Significantly decreased mean C1 and C4 levels were found, and the haemolytic activities of these components were low or low normal in more than 50% of the sera tested. In 15 sera from 5 patients a complement profile characteristic of acquired C1-IHN deficiency was observed. These results indicate that the depression of the activity of the classical complement pathway is a frequently occurring feature in CLL.

Full text

PDF
490

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BALTCH A. L., OSBORNE W., BUNN P. A., CANARILE L., HASSIRDJIAN A. Serum complement and bacteriophage neutralization titers in human infections, leukemias, and lymphomas. J Lab Clin Med. 1960 Oct;56:594–606. [PubMed] [Google Scholar]
  2. Bach-Martensen N., Osther K., Stroyer I. Letter: C1-esterase inactivators and C4 in malignant diseases. Lancet. 1975 Sep 13;2(7933):499–500. doi: 10.1016/s0140-6736(75)90571-1. [DOI] [PubMed] [Google Scholar]
  3. Day N. K., Winfield J. B., Gee T., Winchester R., Teshima H., Kunkel H. G. Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1976 Nov;26(2):189–195. [PMC free article] [PubMed] [Google Scholar]
  4. Füst G., Erdei A., Sármay G., Medgyesi G. A., Gergely J. Functionally active C1 on the surface of human peripheral lymphocytes: its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes. Clin Immunol Immunopathol. 1976 May;5(3):377–387. doi: 10.1016/0090-1229(76)90047-7. [DOI] [PubMed] [Google Scholar]
  5. Gelfand J. A., Boss G. R., Conley C. L., Reinhart R., Frank M. M. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) 1979 Jul;58(4):321–328. doi: 10.1097/00005792-197907000-00004. [DOI] [PubMed] [Google Scholar]
  6. Hauptmann G., Lang J. M., North M. L., Oberling F., Mayer G., Lachmann P. Acquired c1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases. Blut. 1976 Mar;32(3):195–206. doi: 10.1007/BF00995913. [DOI] [PubMed] [Google Scholar]
  7. Johnson A. H., Mowbray J. F., Porter K. A. Detection of circulating immune complexes in pathological human sera. Lancet. 1975 Apr 5;1(7910):762–765. doi: 10.1016/s0140-6736(75)92433-2. [DOI] [PubMed] [Google Scholar]
  8. Kitamura H., Teshima H., Day N. K. The presence of active C1 (C-1) on peripheral human lymphocytes. Vox Sang. 1978;35(4):197–206. doi: 10.1111/j.1423-0410.1978.tb02922.x. [DOI] [PubMed] [Google Scholar]
  9. Leporrier M., Raphaël M., Delcourt A., Leibowitch J. Lymphome nodulaire mixte associé à un déficit en inhibiteur de C1 estérase. Nouv Rev Fr Hematol. 1981;23(4):243–248. [PubMed] [Google Scholar]
  10. Oberling F., Hauptmann G., Lang J. M., Bergerat J. P., Mayer G., Batzenschlager A., Hammann B., Gillet B. Déficits acquis de l'inhibiteur de la C1-estérase au cours de syndrome lymphoïdes. Nouv Presse Med. 1975 Nov 8;4(38):2705–2708. [PubMed] [Google Scholar]
  11. Platts-Mills T. A., Ishizaka K. Activation of the alternate pathway of human complements by rabbit cells. J Immunol. 1974 Jul;113(1):348–358. [PubMed] [Google Scholar]
  12. ROTTINO A., LEVY A. L. Behavior of total serum complement in Hodgkin's disease and other malignant lymphomas. Blood. 1959 Mar;14(3):246–254. [PubMed] [Google Scholar]
  13. SOUTHAM C. M., GOLDSMITH Y. Effect of nitrogen mustard on serum complement in vitro and in patients with neoplastic disease. Proc Soc Exp Biol Med. 1951 Mar;76(3):430–432. doi: 10.3181/00379727-76-18513. [DOI] [PubMed] [Google Scholar]
  14. Schreiber A. D., Zweiman B., Atkins P., Goldwein F., Pietra G., Atkinson B., Abdou N. I. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood. 1976 Oct;48(4):567–580. [PubMed] [Google Scholar]
  15. Yoshikawa S., Yamada K., Yoshida T. O. Serum complement level in patients with leukemia. Int J Cancer. 1969 Nov 15;4(6):845–851. doi: 10.1002/ijc.2910040613. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES